Clinical Trials

Completed Clinical Trial

Panbela has completed a Phase 1 monotherapy study of the safety, tolerability and pharmacokinetics of SBP-101 when administered as monotherapy to subjects with previously-treated metastatic pancreatic ductal adenocarcinoma.

Current Clinical Trials

A Phase 1a/1b study of the safety, tolerability and pharmacokinetics of SBP-101 when administered in combination with gemcitabine and nab-paclitaxel as first line treatment of subjects with metastatic pancreatic ductal adenocarcinoma is currently ongoing in the United States and Australia.